Cardiff Oncology, Inc.
CRDF Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$0.91
KIRA · Stoqly’s AI analyst, in plain words
- Cardiff Oncology, Inc. had $0.6M of revenue in fiscal 2025, down 13.2% on the year before. Over five years, revenue changed +10.1% a year on average.
- Its operating margin was −8,256.3%, down 1,133.2 pts: of every 100 in sales, about −8,256 is left after running the business.
- Cardiff Oncology, Inc. lost $45.9M in fiscal 2025.
- Free cash flow was −$38.0M in fiscal 2025, −6,402.5% of revenue.
Market cap
$62.1M
P/E
—
Revenue
$0.6M
Net income
−$45.9M
Free cash flow
−$38.0M
Operating margin
−8,256.3%
Cardiff Oncology, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−13.2%
No. Sales fell 13.2% last year.
Does it make a profit?
−7,732.0%
No. It lost money last year.
Does profit turn into cash?
−6,402.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Cardiff Oncology, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 24, 2026
- Legal name
- Cardiff Oncology, Inc.
- CIK
- 0001213037
Cardiff Oncology, Inc. · CRDF
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.4M | $0.4M | $0.5M | $0.7M | $0.6M |
| Revenue growth | −1.9% | 7.5% | 26.4% | 40.0% | −13.2% |
| Operating margin | −8,037.6% | −10,337.3% | −9,305.7% | −7,123.1% | −8,256.3% |
| Net income | −$28.3M | −$38.7M | −$41.4M | −$45.4M | −$45.9M |
| Net margin | −7,880.5% | −10,026.9% | −8,492.0% | −6,651.7% | −7,732.0% |
| Diluted EPS | −$0.73 | −$0.89 | −$0.93 | −$0.95 | −$0.69 |
| Cash | |||||
| Cash from operations | −$23.0M | −$33.8M | −$30.9M | −$37.7M | −$37.9M |
| Capital expenditure | $0.2M | $1.0M | $0.6M | $0.1M | $0.0M |
| Free cash flow | −$23.2M | −$34.8M | −$31.5M | −$37.8M | −$38.0M |
| FCF margin | −6,474.9% | −9,022.3% | −6,448.6% | −5,530.5% | −6,402.5% |
| Share count change | 87.0% | 11.7% | 2.5% | 6.7% | 40.3% |
| Debt and strength | |||||
| Cash and short-term investments | $141M | $105M | $74.8M | $91.7M | $58.3M |
| Shareholders' equity | $140M | $106M | $69.7M | $82.9M | $45.4M |
| Current ratio | 22.3x | 14.3x | 7.4x | 7.1x | 3.7x |
| Returns and quality | |||||
| Return on equity | −21.1% | −31.4% | −47.1% | −59.5% | −71.5% |
| Return on tangible equity | −20.2% | −36.4% | −59.5% | −54.8% | −101.1% |
| Piotroski F-score | 2 | 2 | 2 | 3 | 2 |
| Altman Z'' | 15.3 | 6.5 | −5.8 | −4.6 | −20.4 |
Insiders bought, 12 months
$1.1M
2 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cardiff Oncology, Inc. · CRDF
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.91 a share, the company is worth $62.1M.
Source: SEC EDGAR XBRL filings (CIK 0001213037). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.